BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crowley MJ, Powers BJ, Myers ER, Mcbroom AJ, Sanders GD. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization. American Heart Journal 2012;163:777-782.e8. [DOI: 10.1016/j.ahj.2012.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang WW, Bai F, Wang J, Zheng RH, Yang LW, James EA, Zhao ZQ. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor. Drug Des Devel Ther 2017;11:3019-33. [PMID: 29081650 DOI: 10.2147/DDDT.S144807] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
2 Zheng RH, Bai XJ, Zhang WW, Wang J, Bai F, Yan CP, James EA, Bose HS, Wang NP, Zhao ZQ. Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats. Drug Des Devel Ther 2019;13:2745-57. [PMID: 31496651 DOI: 10.2147/DDDT.S213910] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
3 Bai F, Pang XF, Zhang LH, Wang NP, McKallip RJ, Garner RE, Zhao ZQ. Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44-hyaluronan interaction in rats with hypertension and myocardial fibrosis. Life Sci 2016;153:141-52. [PMID: 27085217 DOI: 10.1016/j.lfs.2016.04.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
4 Pang XF, Zhang LH, Bai F, Wang NP, Garner RE, McKallip RJ, Zhao ZQ. Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug Des Devel Ther 2015;9:6043-54. [PMID: 26648693 DOI: 10.2147/DDDT.S95333] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
5 Gorabi AM, Hajighasemi S, Kiaie N, Rosano GMC, Sathyapalan T, Al-Rasadi K, Sahebkar A. Anti-fibrotic effects of curcumin and some of its analogues in the heart. Heart Fail Rev 2020;25:731-43. [PMID: 31512150 DOI: 10.1007/s10741-019-09854-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
6 Pang X, Zhang L, Bai F, Wang N, Ijaz Shah A, Garner R, Zhao Z. RETRACTED: Dual ACE-inhibition and angiotensin II AT1 receptor antagonism with curcumin attenuate maladaptive cardiac repair and improve ventricular systolic function after myocardial infarctionin rat heart. European Journal of Pharmacology 2015;746:22-30. [DOI: 10.1016/j.ejphar.2014.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Fudim M, Dalgaard F, Al-khatib SM, J. Friedman D, Lallinger K, Abraham WT, Cleland JG, Curtis AB, Gold MR, Kutyifa V, Linde C, Schaber DE, Tang A, Ali-ahmed F, Goldstein SA, Kaufman B, Fortman R, Davis JK, Inoue LY, Sanders GD. Future research prioritization in cardiac resynchronization therapy. American Heart Journal 2020;223:48-58. [DOI: 10.1016/j.ahj.2020.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Longo VD, Antebi A, Bartke A, Barzilai N, Brown-Borg HM, Caruso C, Curiel TJ, de Cabo R, Franceschi C, Gems D, Ingram DK, Johnson TE, Kennedy BK, Kenyon C, Klein S, Kopchick JJ, Lepperdinger G, Madeo F, Mirisola MG, Mitchell JR, Passarino G, Rudolph KL, Sedivy JM, Shadel GS, Sinclair DA, Spindler SR, Suh Y, Vijg J, Vinciguerra M, Fontana L. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell 2015;14:497-510. [PMID: 25902704 DOI: 10.1111/acel.12338] [Cited by in Crossref: 335] [Cited by in F6Publishing: 285] [Article Influence: 55.8] [Reference Citation Analysis]
9 Spindler SR, Mote PL, Flegal JM. Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice. Age (Dordr) 2016;38:379-91. [PMID: 27590905 DOI: 10.1007/s11357-016-9948-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
10 Zhang L, Pang X, Bai F, Wang N, Shah AI, Mckallip RJ, Li X, Wang X, Zhao Z. Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart. Cardiovasc Drugs Ther 2015;29:243-55. [DOI: 10.1007/s10557-015-6592-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
11 Soulet F, Kilarski WW, Roux-Dalvai F, Herbert JM, Sacewicz I, Mouton-Barbosa E, Bicknell R, Lalor P, Monsarrat B, Bikfalvi A. Mapping the extracellular and membrane proteome associated with the vasculature and the stroma in the embryo. Mol Cell Proteomics 2013;12:2293-312. [PMID: 23674615 DOI: 10.1074/mcp.M112.024075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
12 Wang ZF, Wang NP, Harmouche S, Philip T, Pang XF, Bai F, Zhao ZQ. Postconditioning attenuates coronary perivascular and interstitial fibrosis through modulating angiotensin II receptors and angiotensin-converting enzyme 2 after myocardial infarction. J Surg Res 2017;211:178-90. [PMID: 28501115 DOI: 10.1016/j.jss.2016.11.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]